Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $18.00

Posted by George Bondi on Oct 3rd, 2026

Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price target raised by Wells Fargo & Company from $14.00 to $18.00 in a research report released on Wednesday,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

Several other equities research analysts have also commented on IOVA. Robert W. Baird set a $6.00 target price on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Barclays increased their price target on shares of Iovance Biotherapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Thursday, September 17th. Citizens Jmp boosted their price objective on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. The Goldman Sachs Group began coverage on shares of Iovance Biotherapeutics in a research report on Thursday, September 24th. They set a “buy” rating and a $15.00 target price on the stock. Finally, UBS Group lifted their price target on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the company a “neutral” rating in a research report on Thursday, August 20th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $12.40.

Check Out Our Latest Stock Report on IOVA

Iovance Biotherapeutics Trading Down 0.1%

Shares of IOVA stock opened at $14.22 on Wednesday. The stock has a 50 day simple moving average of $8.35 and a 200-day simple moving average of $5.48. The company has a market cap of $6.44 billion, a price-to-earnings ratio of -19.48 and a beta of 0.75. Iovance Biotherapeutics has a 12-month low of $1.76 and a 12-month high of $15.30.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. The firm had revenue of $99.31 million for the quarter, compared to the consensus estimate of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The company’s revenue for the quarter was up 65.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.33) earnings per share. On average, equities analysts forecast that Iovance Biotherapeutics will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Iovance Biotherapeutics during the 2nd quarter valued at about $153,744,000. Invenomic Capital Management LP increased its position in Iovance Biotherapeutics by 13.5% during the fourth quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock worth $32,649,000 after purchasing an additional 1,417,897 shares during the last quarter. Palo Alto Investors LP acquired a new position in Iovance Biotherapeutics during the second quarter worth approximately $22,032,229. Bank of America Corp DE acquired a new position in Iovance Biotherapeutics during the second quarter worth approximately $20,773,000. Finally, Dimensional Fund Advisors LP raised its stake in Iovance Biotherapeutics by 71.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,645,702 shares of the biotechnology company’s stock worth $9,282,000 after purchasing an additional 1,106,592 shares during the period. Institutional investors and hedge funds own 77.03% of the company’s stock.

Iovance Biotherapeutics News Roundup

Here are the key news stories impacting Iovance Biotherapeutics this week:

Positive Sentiment: Higher revenue outlook supports the bull case. Iovance’s increased FY2026 revenue guidance is the main catalyst behind the recent advance, signaling stronger expectations for product demand and commercial execution. IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
Positive Sentiment: Analysts are improving earnings expectations. Zacks Research raised its FY2026 EPS forecast to a loss of $0.55 from $0.56, FY2027 to a loss of $0.39 from $0.44, and FY2028 to a loss of $0.03 from $0.07. Several quarterly estimates were also revised higher, with Q3 2028 projected at breakeven. HC Wainwright likewise raised its estimates, maintained a “Buy” rating, and kept a $20 price target. Analyst earnings estimates for Iovance Biotherapeutics
Positive Sentiment: Additional analyst support is helping sentiment. Wells Fargo increased its price target, while the broader consensus target was reported as rising 34.74% to $13.06. Zacks’ earnings-surprise methodology also identified IOVA as a stock investors should monitor for a potential earnings beat. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
Neutral Sentiment: Management strengthened its medical leadership. Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer, adding global drug-development experience in T-cell therapies. The appointment is strategically supportive but is unlikely to materially affect near-term results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
Negative Sentiment: Losses and valuation risks remain. Iovance is still expected to report a full-year loss, and the reported $13.06 consensus target is below the recent trading level. That gap could limit upside or increase volatility if revenue growth fails to meet elevated expectations.

About Iovance Biotherapeutics

(Get Free Report)

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.